Novavax, Inc. (NVAX)

Novavax's stock price has fluctuated significantly in the past six months, increasing by 36.29%. As of April 9, 2026, the share price was $8.54, a 57.27% increase from April 10, 2025. Key events include a profitable Q4 earnings report, a strategic pivot presented at the Leerink Global Healthcare Conference, and a $1.2 billion partnership with Sanofi. Novavax sold its Czech manufacturing facility to Novo Nordisk for $200 million. Activist investor Shah Capital announced plans to vote against the Novavax board, leading to a stock rise. The stock also experienced a dip and recovery following a Wall Street Journal report on its vaccine's FDA status.

Novavax's product pipeline includes vaccines for seasonal influenza and respiratory syncytial virus (RSV), suggesting that demand for some of its products may exhibit seasonality. Vaccines for seasonal infectious diseases typically see increased demand during specific times of the year, often coinciding with flu seasons or periods of higher RSV transmission. The company's focus on seasonal influenza inherently implies a seasonal demand pattern for such a vaccine.

Novavax, Inc. is a biotechnology company focused on developing and commercializing vaccines for infectious diseases, operating in the biological product manufacturing industry. It uses a proprietary technology platform combining recombinant protein-based nanoparticles with its Matrix-M adjuvant. Its major products include Nuvaxovid, a COVID-19 vaccine commercialized by Sanofi, and the R21 Matrix-M adjuvant malaria vaccine. The company's pipeline includes vaccine candidates for influenza, RSV, avian flu, shingles, and Clostridioides difficile.

Novavax is headquartered in Gaithersburg, Maryland, USA, and conducts R&D and manufacturing for its Matrix-M adjuvant in Uppsala, Sweden, through Novavax AB. The company has a global production network across the U.S., Asia, and Europe, with manufacturing partnerships in Europe, Asia, and Africa, including the Serum Institute of India and SK bioscience. The company generates maximum revenue from the United States.

Novavax is committed to developing life-saving innovations and addressing global health challenges through its vaccine technology. The company's reputation is built on its scientific expertise and proven technology platform, including protein-based nanoparticles and the Matrix-M adjuvant. Events affecting Novavax's reputation include a Wall Street Journal report concerning the FDA status of its vaccine and a report of plans to link the COVID shot with child deaths. The company continues to focus on scaling manufacturing capacity and securing regulatory approvals for its vaccine candidates.

Novavax, Inc. has a mixed ownership structure including institutional, retail, and individual investors. Institutional investors own approximately 50.22% to 72.31% of the stock, insiders hold around 0.51% to 17.25%, and public companies and retail investors own approximately 10.44% to 49.27%. Major institutional owners include Vanguard Group Inc., Shah Capital Management, and BlackRock, Inc. Cadila Pharmaceuticals Ltd is a significant individual shareholder, owning 9.50 million shares, representing 5.83% of the company.